Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bryotoxin B is a specific bufadienolide compound isolated from the medicinal plant *Bryophyllum pinnatum* (also known as *Kalanchoe pinnata*). As a member of the bufadienolide class, it is structurally related to cardiac glycosides and is traditionally known for its potential cardiotonic and cytotoxic properties. Recent research, including in silico molecular docking studies, has highlighted its potential therapeutic utility in treating atherosclerosis. These studies suggest that bryotoxin B may act by targeting Adenosine monophosphate-activated protein kinase (AMPK) and Inducible nitric oxide synthase (iNOS), thereby potentially reducing the vascular inflammation and thickening associated with atherosclerotic disease. It is primarily studied as a bioactive constituent of herbal extracts in traditional Indonesian medicine.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on bryotoxin B.